Stock analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.
LadRx Stock Up ∞
Shares of NASDAQ:CYTR opened at $0.09 on Thursday. LadRx has a 12-month low of $0.05 and a 12-month high of $0.86.
Get
LadRx alerts:
About LadRx
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
Featured Articles
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
Stock analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.
斯托克新闻网的股票分析师在周四发给投资者的一份报告中开始报道LadRx(纳斯达克代码:Cytr-Get Rating)的股票。该经纪公司对该股设定了“持有”评级。
LadRx Stock Up ∞
Shares of NASDAQ:CYTR opened at $0.09 on Thursday. LadRx has a 12-month low of $0.05 and a 12-month high of $0.86.
周四,纳斯达克的股价开盘报0.09美元。LadRx的12个月低点为0.05美元,12个月高位为0.86美元。
Get
LadRx
alerts:
About LadRx
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
LadRx公司是一家生物制药研发公司,从事新型抗癌候选药物的发现、研究和临床开发。它专注于开发Linker激活药物释放(LADR)技术平台,这是一个发现引擎,可以帮助创建一条抗癌分子的管道,在避免不可接受的全身毒性的同时,将高效药物直接输送到肿瘤。
Featured Articles
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
- 免费获取StockNews.com关于LadRx的研究报告(Cytr)
- 企业产品合作伙伴是否得到公平评价?
- WhatsApp合作伙伴关系是否会提振MercadoLibre的收益?
- 2023年中型股可能翻一番
- 马伦汽车签署新合作伙伴后股价上涨
- REV集团引领专用车制造商走高
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LadRx Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对LadRx和相关公司的最新新闻和分析师评级的每日简要摘要。